Peer-influenced content. Sources you trust. No registration required. This is HCN.

BloodCOVID-19 and Blood Cancer in the Vaccination Era

We can better understand outcomes in patients with a variety of ages, ethnicities, comorbidities, and exposures by using observational data. It can be challenging or even impossible to disentangle the diverse effects of dynamic elements like vaccination rates, patient behaviors, and COVID-19 pathogenicity. Randomized controlled trials involving blood cancer patients are required to fully assess the impact of COVID-19 therapies. The impact of both bivalent vaccines and prophylactic monoclonal antibodies, as well as ways to assure equitable distribution of COVID-19 vaccines and therapies, will all be determined by future study. Some of those studies must involve people who have hematologic malignancies.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form